BPC-157 vs TB-500: how the two recovery-class peptides actually differ.

If you've read about peptide-based tissue-repair research in the last decade, you've seen BPC-157 and TB-500 mentioned together. They're structurally unrelated and mechanistically distinct, but they show up in adjacent or overlapping experimental contexts often enough that researchers tend to keep both on hand. This guide covers how each compound is built, what research has measured them doing, where they overlap, and how to handle them on the bench.

At a glance

Different scaffolds, related questions

BPC-157 is a fragment from a larger protein isolated in human gastric juice (Body Protection Compound). The 15-residue research sequence is not found in human proteomes as a free peptide — it's a specific cleavage fragment that researchers synthesize chemically. Mechanistic studies attribute its observed activity to upregulation of growth-hormone receptors and modulation of nitric-oxide synthesis, with downstream effects on angiogenesis. Most of the published literature uses rodent injury and ulcer models.

TB-500 is a synthetic version of the 17–43 active sequence of Thymosin β4, a small protein widely expressed in human cells where its primary biochemical role is binding to G-actin to regulate cytoskeleton dynamics. The shorter LKKTETQ motif is the actin-binding signature and the basis for most cell-migration models in the literature. Researchers should know that “TB-500” in catalog usage may refer to either the 17-residue active fragment or the full Tβ4 polypeptide depending on supplier — check the COA molecular weight to confirm which scaffold you have. TB-500 is not currently stocked at Pure North Peptides; see the catalog for what we carry.

Where they overlap, where they don't

• Both appear in vascular and wound-healing research contexts, and both are reported to promote angiogenesis in in-vitro models — via different pathways. That is the strongest mechanistic overlap, and is the reason they get co-referenced.
• BPC-157 only: the bulk of published in-vivo data is in GI and tendon models. Researchers studying gut-barrier integrity or musculoskeletal tissue repair specifically tend to cite BPC-157.
• TB-500 only: cardiac repair and dermal wound studies preferentially cite Tβ4 (and TB-500 as its active fragment). The cytoskeletal-modulation mechanism is the defining one and doesn't share pathway with BPC-157.
• Together: studies running both as comparative reference standards in the same recovery-axis model are not uncommon. Reconstitute and aliquot each vial independently so concentrations can be controlled per compound.

Storage and handling notes

Both peptides are lyophilized and stable at −20 °C, desiccated, for 24+ months from manufacture. After reconstitution with bacteriostatic water:

• Store working solution at 4 °C. Use within 28 days for BPC-157, 14–21 days for TB-500 (the shorter peptide is slightly more degradation-prone in solution at typical buffer pH).
• Aliquot if you anticipate multiple freeze-thaw cycles. TB-500 in particular loses activity faster across freeze-thaws than BPC-157.
• Avoid agitation during reconstitution — gentle swirl, not shake. See peptide reconstitution protocol for technique detail.

Verification: read the COA before the experiment

Every Pure North Peptides lot ships with a Janoshik Analytical COA. For comparative research between BPC-157 and TB-500, the items to confirm are: HPLC purity floor (≥99% for both), molecular-weight identity by LC-MS (1419.5 Da for BPC-157; check expected MW for your TB-500 variant), and LAL endotoxin clearance. The lot number on each vial label cross-references to the published chromatogram at purenorthpeptides.com/lab-results/. If you're running a publishable comparison, archive the COA PDFs alongside your data — reviewers do ask.

FAQ